Alexander Schmitz

Title: Innovations of Alexander Schmitz

Introduction

Alexander Schmitz is a notable inventor based in Kiel, Germany. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target potassium channels. His work has implications for treating various diseases, including autoimmune disorders.

Latest Patents

Schmitz holds 2 patents, with his latest innovations focusing on 5-phenoxyalkoxypsoralens. These compounds are designed for selective inhibition of the voltage-gated Kv1.3 potassium channel. The compositions of matter comprising these compounds are useful in treating diseases or disorders in both human and animal subjects. The therapeutic effects of these compounds may be attributed to their ability to inhibit potassium channels, particularly the Kv1.3 channel. Notably, these compounds exhibit greater selectivity for certain potassium channels compared to others, such as Kv1.5.

Career Highlights

Schmitz is affiliated with the University of California, where he continues to advance research in his field. His work has garnered attention for its potential to provide new treatment options for autoimmune diseases through innovative chemical compounds.

Collaborations

He has collaborated with notable colleagues, including Heike Wulff and Ananthakrishnan Sankaranarayanan, to further enhance the research and development of his patented compounds.

Conclusion

Alexander Schmitz's contributions to the field of medicinal chemistry highlight the importance of innovation in developing new therapeutic options. His work on potassium channel inhibitors represents a significant advancement in the treatment of autoimmune diseases.